Biogen Idec Showcases More Than 70 Data Presentations at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

Extract

---

Biogen Idec Showcases More Than 70 Data Presentations at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

- Company's Franchise Continues to Redefine Success in the Treatment of MS -

CAMBRIDGE, Mass. -- Biogen Idec (NASDAQ: BIIB) today announced more than 70 platform and poster presentations from the company's multiple sclerosis (MS) franchise being presented during the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Dusseldorf, Germany. Held from September 9 -12, 2009, ECTRIMS is the world's largest medical meeting dedicated to MS. Data being presented will include the company's currently marketed products, TYSABRI([R]) (natalizumab) and AVONEX([R]) (Interferon beta-1a), as ...

See the full content of this document

---